The latest announcement is out from Q32 Bio ( (QTTB) ).
On April 25, 2025, Mark Iwicki announced his resignation from the board of directors of Q32 Bio Inc., effective December 31, 2025. He will maintain his roles as Chair of the Board and the Compensation Committee, and as a member of the Audit Committee until then. His resignation is to focus on his CEO role at Inhibikase Therapeutics, Inc., and is not due to any disagreements with Q32 Bio.
Spark’s Take on QTTB Stock
According to Spark, TipRanks’ AI Analyst, QTTB is a Neutral.
Q32 Bio’s overall stock score is low due to significant financial instability, negative revenue, and ongoing losses. The technical analysis shows mixed signals, while the valuation is unattractive with a negative P/E ratio and no dividends. These factors highlight the company’s current financial and operational challenges, suggesting a need for strategic changes to improve its financial health.
To see Spark’s full report on QTTB stock, click here.
More about Q32 Bio
YTD Price Performance: -46.38%
Average Trading Volume: 204,313
Technical Sentiment Signal: Buy
Current Market Cap: $22.57M
Find detailed analytics on QTTB stock on TipRanks’ Stock Analysis page.